Mustang Bio, Inc. (NASDAQ:MBIO) Short Interest Down 32.3% in December

by · The Markets Daily

Mustang Bio, Inc. (NASDAQ:MBIO – Get Free Report) was the recipient of a significant drop in short interest in the month of December. As of December 15th, there was short interest totaling 58,750 shares, a drop of 32.3% from the November 30th total of 86,746 shares. Based on an average daily trading volume, of 79,384 shares, the short-interest ratio is currently 0.7 days. Approximately 0.8% of the shares of the company are sold short. Approximately 0.8% of the shares of the company are sold short. Based on an average daily trading volume, of 79,384 shares, the short-interest ratio is currently 0.7 days.

Mustang Bio Stock Down 1.2%

Mustang Bio stock traded down $0.01 during trading hours on Tuesday, hitting $0.95. 100,094 shares of the company traded hands, compared to its average volume of 83,440. The firm’s 50-day simple moving average is $1.23 and its two-hundred day simple moving average is $1.51. Mustang Bio has a 1-year low of $0.89 and a 1-year high of $21.95.

Mustang Bio (NASDAQ:MBIO – Get Free Report) last announced its earnings results on Friday, November 7th. The company reported ($0.07) EPS for the quarter. On average, analysts expect that Mustang Bio will post -35 EPS for the current fiscal year.

Institutional Trading of Mustang Bio

A hedge fund recently bought a new stake in Mustang Bio stock. Anson Funds Management LP bought a new position in shares of Mustang Bio, Inc. (NASDAQ:MBIO – Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 45,716 shares of the company’s stock, valued at approximately $57,000. Anson Funds Management LP owned approximately 1.04% of Mustang Bio as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 9.95% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Mustang Bio in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Mustang Bio has a consensus rating of “Sell”.

Check Out Our Latest Analysis on Mustang Bio

About Mustang Bio

(Get Free Report)

Mustang Bio, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cell and gene therapies for oncology and rare genetic diseases. The company’s primary platform leverages chimeric antigen receptor T‐cell (CAR-T) technology to target both hematologic and solid tumor indications. In parallel, Mustang Bio is advancing a portfolio of lentiviral‐based gene therapy candidates designed to address inherited metabolic disorders with high unmet medical need.

The company’s oncology pipeline includes programs directed at B-cell malignancies and aggressive brain tumors, with lead CAR-T candidates in clinical trials for glioblastoma multiforme and various B-cell leukemias and lymphomas.

See Also